Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Ligand to Report Third Quarter Financial Results on November 7

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report third quarter 2022 financial results after the close of the U.S. financial markets on Monday, November 7, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand's CEO John Higgins, President and COO Matt Korenberg and CFO Tavo Espinoza.

Conference Call and Webcast Information


Ligand conference call to discuss financial results and provide general business updates



Monday, November 7, 2022



4:30 p.m. Eastern time (1:30 p.m. Pacific time)


Conference Call:

Dial (646) 960-0369

Conference ID is 6501694



Live and replay webcast of the call are available here.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) ultimately to generate our revenue. Ligand's Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand's Pelican Expression Technology® is a robust, validated, cost-effective and scalable platform for recombinant protein production that is especially well-suited for complex, large-scale protein production where traditional systems are not. Ligand has established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Sanofi, Janssen, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com.

Follow Ligand on Twitter @Ligand_LGND.

We use Twitter and our investor relations website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our Twitter account and our website, in addition to following our press releases, SEC filings, public conference calls and webcasts.

These press releases may also interest you

at 08:51
The National Pressure Injury Advisory Panel (NPIAP) is pleased to be celebrating our 35th Anniversary. The organization was formed when a multidisciplinary group of 15 concerned healthcare professionals, led by Dr. Thomas P. Stewart, held their first...

at 08:44
Medical Technology Associates, LLC (MTA) is pleased to announce the acquisition of Energy Plus, Inc and its family of companies headquartered in Harrisburg, PA. Energy Plus is a recognized leader in Controlled Environments with an extensive portfolio...

at 08:43
Board-certified celebrity plastic surgeon Dr. Alexis Parcells, MD was recently featured as a labiaplasty expert on POOSH, a digital lifestyle and wellness platform founded by Kourtney Kardashian. Labiaplasty, once considered taboo, has exploded in...

at 08:40
The "Focused Ion Beam Market by Ion Source (Ga+ Liquid Metal, Plasma, Gas Field), Application (Failure Analysis, Nanofabrication, Device Modification, Circuit Edit, Counterfeit Detection), Vertical and Region - Global Forecast to 2028" report has...

at 08:39
The Joint Corp. , the nation's largest provider of chiropractic care through The Joint Chiropractic® network, has been named to Entrepreneur magazine's Franchise 500® ranking for 2023. After achieving a No. 57 ranking in 2022, The Joint moves up five...

at 08:39
Black Rock Nutraceuticals today announced its expanded lineup of Nápreva for people and Nápreva K9 for dogs.  Nápreva is a dietary supplement comprised of concentrated sage, West African black pepper, Japanese cypress and avocado terpenes formulated...

News published on 26 october 2022 at 18:05 and distributed by: